- $1.27bn
- $1.49bn
- $198.96m
- 56
- 12
- 94
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 26.15 | ||
| PEG Ratio (f) | 0.32 | ||
| EPS Growth (f) | 465.25% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 409.83 | ||
| Price to Sales | 5.66 | ||
| EV to EBITDA | 41.4 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.24% | ||
| Return on Equity | n/a | ||
| Operating Margin | 13.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 63.04 | 65.14 | 75.44 | 99.77 | 198.96 | 272.29 | 338.55 | 48.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +126.09 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Directors
- James Shannon NEC (64)
- Michael Castagna CEO (44)
- Steven Binder CFO (58)
- Stuart Tross CHO (54)
- David Thomson EVP (54)
- Joseph Kocinsky CTO (57)
- Ronald Consiglio IND (77)
- Michael Friedman IND (77)
- Jennifer Grancio IND (49)
- Anthony Hooper IND (66)
- Sabrina Kay IND (58)
- Kent Kresa IND (82)
- Christine Mundkur IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 14th, 1991
- Public Since
- July 28th, 2004
- No. of Shareholders
- 102
- No. of Employees
- 414
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 272,315,846
- Address
- 1 Casper Street, DANBURY, 06810
- Web
- https://mannkindcorp.com/
- Phone
- +1 8186615000
- Auditors
- Deloitte & Touche LLP
Upcoming Events for MNKD
Q3 2024 MannKind Corp Earnings Release
Similar to MNKD
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the MannKind share price?
As of Today at 21:57 UTC, shares in MannKind are trading at $4.67. This share price information is delayed by 15 minutes.
How has the MannKind share price performed this year?
Shares in MannKind last closed at $4.67 and the price had moved by +13.35% over the past 365 days. In terms of relative price strength the MannKind share price has underperformed the S&P500 Index by -8.87% over the past year.
What are the analyst and broker recommendations for MannKind?
The overall consensus recommendation for MannKind is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the MannKind dividend yield?
MannKind does not currently pay a dividend.
Does MannKind pay a dividend?
MannKind does not currently pay a dividend.
When does MannKind next pay dividends?
MannKind does not currently pay a dividend.
How do I buy MannKind shares?
To buy shares in MannKind you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MannKind?
As of the previous close price of $4.67, shares in MannKind had a market capitalisation of $1.27bn.
Where are MannKind shares listed?
Here are the trading details for MannKind:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: MNKD
What kind of share is MannKind?
Based on an overall assessment of its quality, value and momentum MannKind is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MannKind share price forecast for 2024?
The analyst consensus target price for shares in MannKind is $7.08. That is 51.61% above the last closing price of $4.67.
Analysts covering MannKind currently have a consensus Earnings Per Share (EPS) forecast of $0.12 for the next financial year.
What is the trend in the MannKind share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MannKind. Over the past six months, its share price has outperformed the S&P500 Index by +12.77%.
As of the last closing price of $4.67, shares in MannKind were trading +14.62% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MannKind PE Ratio?
The MannKind PE ratio based on its reported earnings over the past 12 months is 26.15. The shares last closed at $4.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MannKind?
MannKind's management team is headed by:
- James Shannon - NEC
- Michael Castagna - CEO
- Steven Binder - CFO
- Stuart Tross - CHO
- David Thomson - EVP
- Joseph Kocinsky - CTO
- Ronald Consiglio - IND
- Michael Friedman - IND
- Jennifer Grancio - IND
- Anthony Hooper - IND
- Sabrina Kay - IND
- Kent Kresa - IND
- Christine Mundkur - IND